Press Release

California Court Orders in Favor of Plexxikon in Dispute with Novartis

Tokyo – (October 3, 2022) – Daiichi Sankyo (TSE: 4568) today announced that the U.S. District Court for the Northern District of California has issued an order sustaining a jury verdict in favor of Plexxikon Inc. (its U.S. subsidiary whose offices closed in March 2022), (hereinafter "Plexxikon") on its claim that Novartis Pharmaceuticals Corporation's BRAF inhibitor Tafinlar® infringes Plexxikon's U.S. Patents 9,469,640 and 9,844.539 ("the patents"). The case was filed by Plexxikon in August 2017.

The order directs Novartis to pay $177.8 million in damages and a 9% royalty on U.S. sales of Tafinlar® until the expiration of the patents of Plexxikon. The Court reversed the jury's finding of willful infringement by Novartis.

Any impact on Daiichi Sankyo's consolidated financials for fiscal year ending March 31, 2023, is currently being evaluated and will be announced as soon as possible.

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an "Innovative Global Healthcare Company Contributing to the Sustainable Development of Society." For more information, please visit: *www.daiichisankyo.com*.

Media Contacts:

Global/Japan:
Masashi Kawase
Daiichi Sankyo Co., Ltd.
kawase.masashi.a2@daiichisankyo.co.jp
+81 3 6225 1126 (office)

Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp